Innovent's PECONDLE® Achieves Significant Efficacy in Phase 3 CLEAR-2 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 day ago0mins
- Significant Efficacy: Innovent's PECONDLE® achieved PASI 90 responses of 89.3% and 90.1% in the CLEAR-2 trial, significantly outperforming control groups, demonstrating its superior long-term efficacy in moderate-to-severe psoriasis patients.
- Favorable Safety Profile: Throughout the trial, PECONDLE® showed no new safety signals, maintaining a consistent safety profile compared to previous studies, thus providing a reliable treatment option for patients.
- Convenient Treatment: By utilizing quarterly dosing, PECONDLE® not only achieved deep and durable remission but also significantly reduced relapse risk, addressing patients' needs for long-term management.
- Broad Market Potential: As China's first self-developed IL-23p19 monoclonal antibody, PECONDLE®'s success lays a solid foundation for the promotion of innovative biopharmaceuticals in domestic and international markets, expected to drive future business growth for Innovent.
01801.HK
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on 01801
Wall Street analysts forecast 01801 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01801 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 84.400
Low
Averages
High
Current: 84.400
Low
Averages
High
JPMorgan
JPMorgan
maintain
$110
2025-12-09
New
Reason
JPMorgan
JPMorgan
Price Target
$110
2025-12-09
New
maintain
Reason
The analyst rating from JPMorgan for INNOVENT BIO is "Overweight." The reasoning behind this rating includes:
1. Market Potential: The weight loss drug market in China is considered vast, providing significant opportunities for multiple blockbuster drugs, which supports optimism about INNOVENT BIO's prospects.
2. Product Pipeline: JPMorgan is optimistic about INNOVENT BIO's product pipeline, which covers various fields such as oncology, autoimmune diseases, metabolic diseases, and ophthalmology.
3. Flexible Pricing Strategy: Despite concerns regarding competition from Eli Lilly's tirzepatide, JPMorgan believes that INNOVENT BIO's mazdutide can adopt a flexible pricing strategy in response to market changes.
4. Future Growth Forecast: The broker forecasts that by 2027, INNOVENT BIO will have more than ten products on the market, with projected sales reaching RMB17 billion.
Overall, these factors contribute to a positive outlook for the company, justifying the "Overweight" rating.
CCBI
CCBI
Outperform
maintain
$125 -> $128
2025-11-07
Reason
CCBI
CCBI
Price Target
$125 -> $128
2025-11-07
maintain
Outperform
Reason
The analyst rating for INNOVENT BIO was influenced by several positive factors highlighted in the article. The company's total product revenue for 3Q25 grew by over 40% year-over-year, exceeding expectations and surpassing the broker's full-year growth forecast of 37%. Additionally, the revenue increased by 22% quarter-over-quarter, which was a faster pace compared to the previous year.
CCBI, the research firm, views INNOVENT BIO as a leader in China's biologics market for treating challenging chronic and fatal diseases, prompting them to raise their revenue forecasts for the company for 2025-27. They also increased the adjusted earnings forecasts for the same period. As a result of these strong performance indicators and positive outlook, CCBI raised the target price for INNOVENT BIO from HKD 125 to HKD 128 while maintaining an "Outperform" rating.
CMBI
CMBI
Buy
maintain
2025-10-24
Reason
CMBI
CMBI
Price Target
2025-10-24
maintain
Buy
Reason
The analyst rating for INNOVENT BIO was maintained at "Buy" due to the announcement of a global strategic partnership with Takeda Pharmaceutical, which includes significant upfront payments and potential milestone payments that enhance the company's financial outlook. CMBI expressed optimism about the global development of key oncology assets IBI363 and IBI343, leading to an increase in the target price from $109.48 to $110.62 based on the discounted cash flow (DCF) method.
JPMorgan
JPMorgan
maintain
$114 -> $110
2025-10-23
Reason
JPMorgan
JPMorgan
Price Target
$114 -> $110
2025-10-23
maintain
Reason
The analyst rating for INNOVENT BIO was reaffirmed as "Overweight" by JPMorgan due to the company's recent global collaboration agreement with Takeda Pharmaceutical, which includes a significant upfront payment and potential milestone payments. This agreement is seen as a strategic move that strengthens INNOVENT BIO's market position in the US and enhances its capabilities for independent global clinical development and commercialization. Despite trimming the target price from $114 to $110, the overall outlook remains positive, leading to the continued endorsement as a top pick in China's biopharma sector.
See All Ratings
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?